Special Issue

Natural Compounds as Potential Anticancer Agents

Message from the Guest Editor

Surgical resection, chemotherapy and radiation are the accepted medical practices in cancer treatment. Nonetheless, these treatment strategies (chemotherapy and radiation) may induce a plethora of adverse effects and drug tolerance over time. Alternate forms to the commonly used medical practices are therefore pertinent. The scope and aims of this Special Issue are to compile articles, original research, clinical trials, and/or review that address the latest developments in alternate therapies using natural compounds. In this issue, natural products will include molecules obtained from animals, plants or insects and is not restricted to bioactive molecules only. Studies that focus on the mechanistic action of these natural products and their relevance to chemotherapy will be accepted for this issue.

Guest Editor

Dr. Sabita Saldanha

Department of Biological Sciences, Alabama State University, 1627 Harris Way, Montgomery, AL 36101, USA

Deadline for manuscript submissions

closed (31 July 2019)



Medicines

an Open Access Journal by MDPI

Indexed in PubMed



mdpi.com/si/18487

Medicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicines@mdpi.com

mdpi.com/journal/ medicines





Medicines

an Open Access Journal by MDPI

Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).

